RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back
| Autor: | Randall Kaye, Kayla Torres, Sanam Ara Vaughan |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Male
Spasm Tolperisone medicine.drug_class 03 medical and health sciences 0302 clinical medicine Back pain medicine Humans 030212 general & internal medicine Back strain Muscle Relaxants Central business.industry Skeletal muscle Muscle relaxant General Medicine Low back pain Clinical trial Treatment Outcome medicine.anatomical_structure Back Pain Anesthesia Female medicine.symptom business 030217 neurology & neurosurgery muscle spasm medicine.drug |
| Zdroj: | Pain Management. 12:25-33 |
| ISSN: | 1758-1877 1758-1869 0467-1082 |
| DOI: | 10.2217/pmt-2021-0041 |
| Popis: | Tolperisone is a nonopioid, centrally acting muscle relaxant in clinical development in the USA for the treatment of symptoms associated with acute, painful muscles spasms of the back. CLN-301, RESUME-1, is a 14-day double-blind, randomized, placebo-controlled, parallel-group Phase III study of the efficacy and safety of tolperisone administered orally three-times daily in 1000 male and female subjects at approximately 70 clinical sites in the USA experiencing back pain due to or associated with muscle spasm of acute onset. Tolperisone is a promising therapeutic for managing acute, painful muscle spasms of the back as it appears to lack the off-target CNS effects often seen with conventional skeletal muscle relaxants. Clinical Trials registration number: NCT04671082 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|